This website is intended for U.S. residents only. This website contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, or in different dosages. Nothing contained herein should be considered a solicitation, promotion or advertisement for any drug including those under development. Any information on the products contained herein is not intended to provide medical advice nor should be used as a substitute for the advice provided by your physician or other healthcare provider.
- 2018
- 2017
- 2016
- 2015
- 2014
- 2013
- 2012
- 2011
- 2010
- 2009
- APP for exercise programs BANDAI NAMCO Entertainment
- Quethera
Gene therapy program for glaucoma - Rosiptor Aquinox
IC/BPS - Immunostimulating Gene
Loading Oncolytic VirusTottori University - Universal Cells
- Mitobridge
- Ogeda
- MAPS vaccineAffinivax
Pneumococcal Disease - Quetiapine FumarateKyowa
- AU-935
AurationTMP
- QutenzaGrünenthal
- Ganymed
- ASP015K Topical derma
Maruho - CK-2127107 Cytokinetics ALS
- MucoRiceUniv of Tokyo
cholera - BAFF/APRIL antagonists
Thunderbolt pharma - AAV-mVChR1Clino
Retinitis Pigmentosa
- PSCA/CAR-TBellicum
Oncology - Derma assetsLeo Pharma
- Ocata
- LAMP-vaxImmunomic
Allergy - CC-8464Neuropathic Pain
Chromocell - Kanyos Bio Celiac Disease and Type 1 Diabetes
- Immuno-oncology Therapeutics Potenza
- SitagliptinMSD
FDC w/ipragliflozin - Monoclonal Antibody MD Anderson
AML - JRC2-LAMP-vaxImmunomic
JRC pollinosis
- CK-2127107Cytokinetics
NMD - Dana-Farber Cancer Institute K-Ras-
- Harvard Medical School RP
- Cancer Research UK
Aotophagy - ClearPath
- Transfenic silkworms IBL
- MitokyneMitochondria
related disease - ASP1941MSD
Co-promotion - IpragliflozinMSD
Co-promotion - ASG-15ME Seattle Genetics
- CK-2127107Cytokinetics
Muscle weakness - AABPJapan JV
with Amgen - ASP7035Drais
Nocturia - AmbrxADC technology
- ASP015KJanssen
RA - ASP7147Drais
IBS-d - ASP3291Drais
Ulcerative colitis - Dificlir™ (EU) Optimer C.diff infection
- Argamate™ Jelly Sanwa Kagaku Hyperkalemia
- Cimzia™ UCB RA
- PSN821/842AstraZeneca
- RIKENCo-research for
Alzheimer’s - Fully-human mAbEVEC
Infectious disease - VernakalantMSD
- TransVax™Vical
CMV DNA vaccine - DPP-IV RoyaltyRoyalty Pharma
- Perseid
- Tivozanib AVEO RCC, etc.
- Merger & acquisition
- Global / multi-region collaboration
- Regional collaboration
- Technology / research collaboration
- Divestiture / out-licensing
Oct, 23, 2018 Astellas and BANDAI NAMCO Entertainment to Jointly Develop Smartphone Exercise Support App
May, 10, 2018 Aquinox and Astellas Announce Exclusive Licensing Agreement for Rosiptor in the Asia-Pacific Region Including Japan
Feb, 14, 2018 Astellas Acquires Universal Cells, Inc.
Dec, 1, 2017 Astellas Acquires Mitobridge Under Existing Collaboration
Apr, 3, 2017 Astellas to Acquire Ogeda SA
Feb, 28, 2017 Astellas and Affinivax Announce Worldwide Partnership for MAPS Vaccine targeting Pneumococcal Disease
Jan, 31, 2017 Astellas Executes License Agreement with Auration Biotech for the Development and Commercialization of AU-935
Dec, 12, 2016 Astellas Announces Transfer of Qutenza to Grünenthal
Jul, 28, 2016 CYTOKINETICS AND ASTELLAS ANNOUNCE OPTION RIGHT FOR TIRASEMTIV AND EXPANSION OF GLOBAL COLLABORATION FOR CK-2127107 IN ALS
Feb, 01, 2016 Astellas and CLINO Announce License Agreement to Develop and Commercialize Gene Therapy to Treat Retinitis Pigmentosa
Dec, 11, 2015 Bellicum and Astellas Announce License Agreement for Cancer Target PSCA in Cell and Gene Therapy
Nov, 20, 2015 Astellas Commences Tender Offer to Acquire All Outstanding Shares of Ocata Therapeutics
Nov, 18, 2015 Presentation for Astellas to Acquire Ocata Therapeutics
Nov, 11, 2015 Astellas Transfers Its Global Dermatology Business to LEO Pharma
Oct, 09, 2015 Astellas Pharma and Immunomic Therapeutics Announce Worldwide Partnership for LAMP-vax™ Products for Allergic Disease
Apr, 03, 2015 MD Anderson, Astellas Pharma Sign Option Agreement for Monoclonal Antibody Drug Targeting Acute Myeloid Leukemia
Aug, 08, 2014 CANCER RESEARCH UK AND CANCER RESEARCH TECHNOLOGY JOIN FORCES WITH ASTELLAS ON AUTOPHAGY TO FIND NEW CANCER TREATMENTS
Sep, 02, 2013 Astellas and MSD Enter Co-Promotion Agreement in Japan for Ipragliflozin, SGLT2 Inhibitor for Treatment of Type 2 Diabetes
Jun, 26, 2013 CYTOKINETICS AND ASTELLAS ANNOUNCE COLLABORATION IN THE FIELD OF SKELETAL MUSCLE ACTIVATION
May, 29, 2013 AMGEN AND ASTELLAS ANNOUNCE JAPAN ALLIANCE Innovative Joint Venture to Address Unmet Medical Needs of Patients in Japan
May, 07, 2013 Astellas and Drais Partner To Develop Third Astellas Compound through Tacurion
Jun, 04, 2012 Astellas and Drais Partner To Develop Second Astellas Compound through Seldar
Apr, 25, 2012 Astellas and Drais Partner To Develop Astellas Compound through Telsar
Feb, 20, 2012 Astellas Pharma & Sanwa Kagaku Kenkyusho Establish Strategic Alliance in Japan's Pharmaceutical Market for Kidney Diseases
Feb, 01, 2012 UCB and Astellas announce agreement to jointly develop and commercialize Cimzia® (certolizumab pegol) in Japan
Dec, 21, 2011 AstraZeneca Enters into Option Agreement to Acquire New Class of Diabetes Assets from Prosidion
Sep, 05, 2011 Astellas Pharma signs a license agreement with Evec for a fully-human antibody
Jul, 27, 2011 Merck to Acquire Rights to Vernakalant i.v. in Canada, Mexico andthe United States from Astellas (pdf 30KB)
Jul, 15, 2011 Vical and Astellas Announce Worldwide License Agreements for TransVax™ Cytomegalovirus Vaccine
May, 17, 2011 Astellas and Maxygen Announce Completion of Acquisition of Perseid by Astellas
May, 17, 2011 Astellas and AVEO Pharmaceuticals Enter into Worldwide Agreement to Develop and Commercialize Tivozanib Outside of Asia
Dec, 08, 2010 Astellas Pharma Enters Strategic Equity Deal with Cytori ; To Purchase $10 Million in Equity at $7.00 per Share
Nov, 01, 2010 Astellas Pharma Inc.: Enter into Option Agreement with Alavita to Acquire Diannexin Assets
Oct, 19, 2010 Astellas and ASKA Enter into License Agreement for AKP-002
Jul, 28, 2010 Astellas to Pay $295 Million to Extend License of Regeneron's VelocImmune® Antibody Technology through 2023
May, 17, 2010 Astellas Pharma Inc. to Acquire OSI Pharmaceuticals, Inc.
Feb, 24, 2010 Entered into Global Partnership with Basilea for an Azole Antifungal Agent Isavuconazole
Nov, 24, 2009 Seattle Genetics and Agensys, an Affiliate of Astellas, Expand Antibody-Drug Conjugate Collaboration
Nov, 10, 2009 Ironwood and Astellas Announce Japan Licensing Agreement for Linaclotide
Aug, 26, 2009 Pfizer and Astellas Announce Co-promotion Agreement for Caduet® Combination Tablets
Jul, 01, 2009 Astellas Announces Joint Venture with Maxygen to Develop Protein Pharmaceuticals
Jun, 23, 2009 NeurogesX and Astellas Enter Commercialization Agreement for Qutenza TM